

Baseline characteristics of the ALIGN trial: a Phase 3 randomized, double-blind, placebo-controlled clinical trial of atrasentan in patients with IgAN

Hiddo J. L. Heerspink,¹ Meg Jardine,² Donald E. Kohan,³ Richard A. Lafayette,⁴ Adeera Levin,⁵ Adrian Liew,⁶ Hong Zhang,⁷ Todd Gray,⁸ Khushboo Sheth,⁸ Marianne Camargo,^{8*} Ronny Renfurm,⁹ Andrew King,⁸ Jonathan Barratt¹⁰

¹University Medical Center Groningen, Groningen, Netherlands; ²University of Sydney, Sydney, NSW, Australia; ³University of Utah Health, Salt Lake City, UT, United States; ⁴Stanford University, Stanford, CA, United States; ⁵The University of British Columbia, Vancouver, BC, Canada; ⁶Mount Elizabeth Novena Hospital, Singapore, Singapore; ⁷Peking University First Hospital, Beijing, Beijing, China; ⁸Chinook Therapeutics, A Novartis Company, Seattle, WA, United States; ⁹Novartis Pharmaceuticals AG, Basel, Switzerland; ¹⁰University of Leicester, Leicester, Leicestershire, United Kingdom; *Former employee of Chinook Therapeutics.



Scan to obtain:

- Poster
- e-poster

<https://bit.ly/IKWCWN>

Copies of this poster obtained through Quick Response (QR) code are for personal use only and may not be reproduced without permission of the authors.

SUMMARY

- ALIGN is designed to assess the effect of atrasentan, compared with placebo, in reducing proteinuria and eGFR decline in adult patients with IgAN receiving an optimized dose of an ACEi or ARB
- Baseline demographics and patient characteristics show that ALIGN has enrolled a globally representative population of patients with IgAN
 - Most patients were recruited in Asia, where the prevalence of IgAN and other glomerular disease is higher than in the rest of the world
 - Women are well represented in ALIGN with a participation rate >40%
- ALIGN is anticipated to provide unique insights into a potential new treatment option for patients with IgAN

This study is sponsored by Chinook Therapeutics, a Novartis Company
Poster presented at the World Congress of Nephrology 2024, Buenos Aires, Argentina, April 13–16, 2024

INTRODUCTION

- Lifestyle modification and either an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB) are the current treatment options for IgA nephropathy (IgAN)¹
 - While this approach slows the rate of kidney function loss in most patients, residual kidney function loss exceeds the target needed to avoid a lifetime risk of kidney failure²
- In patients with IgAN, upregulation of endothelin-1 exerts deleterious effects through binding to the endothelin A receptor³
- Atrasentan is a potent and selective endothelin A receptor antagonist
- Interim results from the Phase 2 AFFINITY trial show that atrasentan plus optimized ACEi or ARB treatment was well tolerated and resulted in clinically meaningful proteinuria reductions at 12 and 24 weeks⁴
- ALIGN is a Phase 3, randomized, double blind, placebo-controlled study to assess the efficacy and safety of atrasentan vs placebo in adult patients with IgAN receiving optimized ACEi or ARB treatment
- The sodium-glucose co-transporter 2 inhibitor (SGLT2i), dapagliflozin, has been shown to reduce the risk of progression to chronic kidney disease in patients with IgAN⁵
 - ALIGN includes an exploratory cohort to address potential additive effects of atrasentan and SGLT2i

METHODS


- **Key inclusion criteria:** men and women aged ≥18 years, with biopsy-proven IgAN receiving maximally tolerated and optimized dose of a RAS inhibitor (stable for at least 12 weeks before screening) with total urine protein ≥1 g/day and eGFR of at least 30 mL/min/1.73 m². *Exploratory SGLT2i stratum only:* on a stable dose of an SGLT2i plus maximally tolerated and optimized dose of a RAS inhibitor that have been stable for at least 12 weeks prior to screening
- **Key exclusion criteria:** concurrent diagnosis of another cause of chronic kidney disease; clinical suspicion of rapidly progressive glomerulonephritis or Henoch-Schönlein Purpura (IgA vasculitis); clinical diagnosis of nephrotic syndrome; brain natriuretic peptide of >200 pg/mL at screening; hemoglobin below 9 g/dL at screening or prior history of blood transfusion for anemia within 3 months of screening; or history of organ transplantation (apart from corneal transplant); received any investigational agent/approved IgAN treatment (other than a RAS inhibitor) including SGLT2i (except for subjects in the exploratory SGLT2i stratum) within 1 month (or 5 half-lives, whichever is longer) before screening
- **Primary endpoint:** change in proteinuria (urine protein-creatinine ratio [UPCR] based on 24-hour urine collection) from baseline to Week 36 in the main stratum
- **Key secondary endpoint:** change from baseline to Week 136 in eGFR in the main stratum
- **Safety endpoints:** type, incidence, severity, seriousness, and relatedness of treatment-emergent adverse events and incidence, severity, seriousness, and relatedness of adverse events of special interest

RESULTS

Patients

- Patients were enrolled at 133 clinical practice sites across 20 countries worldwide
- 340 patients with biopsy-proven IgAN were randomized to receive 0.75 mg atrasentan or placebo daily orally for 132 weeks (main stratum; **Figure 1**)
- 64 patients receiving a stable dose of SGLT2i were enrolled to an exploratory SGLT2i stratum
- Patients that were randomized and received at least one dose of the assigned treatment are reported here (n=339)

Figure 1



Baseline demographics

Main stratum

- Mean age (SD): 44.7 (12.0) years
- Sex distribution: 143 (42.2%) women; 196 (57.8%) men
- Race: 54.9% Asian; 35.4% white; 1.5% black/African American; 1.5% American Indian/Alaska Native
- Recruitment locations: Asia (45.4%); Latin America/Caribbean (20.6%); North America (15.6%); Europe (12.1%); Oceania (6.2%)

Exploratory SGLT2i stratum

- Participants randomized to this exploratory stratum generally had similar characteristics to those in the main stratum
- Patients in this stratum were slightly older, with more white than Asian people, and were more likely to be recruited in Europe/North America

Table 1. Baseline demographic characteristics (main stratum and exploratory SGLT2i stratum)

Demographic	Total main stratum final analysis (n=339) ¹	Total SGLT2i stratum (n=64)
Age, years, mean (SD)	44.7 (12.0)	47.2 (12.0)
Sex, n (%)		
Male	196 (57.8)	38 (59.4)
Female	143 (42.2)	26 (40.6)
Ethnicity, n (%)		
Hispanic or Latino	75 (22.1)	6 (9.4)
Not Hispanic or Latino	255 (75.2)	55 (85.9)
Not Reported	9 (2.7)	3 (4.7)
Race, n (%)		
American Indian/Alaska Native	5 (1.5)	0
Asian	186 (54.9)	26 (40.6)
Black or African American	5 (1.5)	1 (1.6)
Native Hawaiian/Other Pacific Islander	0	0
White	120 (35.4)	34 (53.1)
Not Reported	4 (1.2)	3 (4.7)
Other ¹	19 (5.6)	0
Geographic Region, n (%)		
Asia	154 (45.4)	16 (25.0)
Europe	41 (12.1)	21 (32.8)
North America	53 (15.6)	21 (32.8)
Latin America and the Caribbean	70 (20.6)	2 (3.1)
Oceania	21 (6.2)	4 (6.3)

¹Includes patients with multiple races reported

²One randomized participant did not start study medication and was withdrawn

Patient characteristics

Main stratum

- Mean duration of IgAN (SD): 5.5 (5.9) years
- Baseline UPCR:
 - Median UPCR g/g (interquartile range): 1.4 (1.1, 2.0)
 - UPCR <1500 mg/g: 54%; UPCR ≥1500 mg/g: 46%
- Baseline eGFR, mean (SD):
 - eGFR: 58.7 (23.8) mL/min/1.73 m²
- eGFR category, n (%):
 - eGFR ≤45 mL/min/1.73 m²: 132 (38.9%)
 - eGFR >45 and <60 mL/min/1.73 m²: 71 (20.9%)
 - eGFR >60 mL/min/1.73 m²: 136 (40.1%)

- RAS inhibitor use at baseline:
 - 100 (29.5%) patients were on an ACEi
 - 236 (69.6%) were on an ARB
- 8 (2.4%) patients were taking SGLT2i

Exploratory SGLT2i stratum

- Baseline characteristics were broadly similar to the main stratum
- Exception of a slightly lower mean (SD) eGFR: 53.0 (22.2) mL/min/1.73 m²

Table 2. Baseline clinical characteristics (main stratum and exploratory SGLT2i stratum)

Characteristic	Total main stratum (n=339) ¹	Total SGLT2i stratum (n=64)
BMI, kg/m²	27.3 (6.0)	28.2 (7.1)
Duration of disease, years	5.5 (5.9)	5.7 (5.5)
Blood pressure		
SBP, mmHg Mean (SD)	124.1 (12.7)	125.8 (12.9)
DBP, mmHg Mean (SD)	79.2 (9.2)	81.2 (9.7)
24-hr UPCR, g/g Median (Q1, Q3)	1.4 (1.1, 2.0)	1.4 (1.0, 2.0)
Baseline 24-hr UPCR category, n (%)		
< 1500 mg/g	183 (54.0)	37 (57.8)
≥ 1500 mg/g	156 (46.0)	27 (42.2)
eGFR, mL/min/1.73 m²		
Mean (SD)	58.7 (23.8)	53.0 (22.2)
Median (Q1, Q3)	52.5 (39.0, 74.0)	45.0 (35.0, 68.5)
eGFR category, n (%)		
≤ 45 mL/min/1.73 m ²	132 (38.9)	33 (51.6)
> 45 and ≤ 60 mL/min/1.73 m ²	71 (20.9)	9 (14.1)
> 60 mL/min/1.73 m ²	136 (40.1)	22 (34.4)
Hemoglobin, g/dL, mean (SD)	13.7 (1.7)	14.4 (1.6)
RAS inhibitor usage at baseline, n (%)		
None ²	3 (0.9)	0
ACE inhibitor use only	100 (29.5)	19 (29.7)
ARB use only	236 (69.6)	44 (68.8)
Both ACE inhibitor and ARB use	0	1 (1.6)
RAS inhibitor tolerance, n (%)		
Tolerant	336 (99.1)	64 (100)
Intolerant	3 (0.9)	0
Baseline SGLT2i medication n (%)		
Any baseline SGLT2i medication	8 (2.4)	60 (93.8)
Dapagliflozin	7 (2.1)	54 (84.4)
Empagliflozin	1 (0.3)	4 (6.3)
Canagliflozin	0	2 (3.1)

¹One randomized participant did not start study medication and was withdrawn. ²Per protocol, patients who were intolerant to RAS inhibitors were eligible; however, the total percentage could not exceed ~5% of total population randomized in the main stratum. ACEi: angiotensin-converting enzyme inhibitor; ARB: angiotensin II receptor blocker; BMI: body mass index; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; SBP: systolic blood pressure; SD: standard deviation; SGLT2i: sodium-glucose co-transporter 2 inhibitor; UPCR: urine protein-creatinine ratio

CONCLUSIONS

- ALIGN has enrolled a globally representative range of patients with IgAN
 - Most patients were recruited in Asia, where the prevalence of IgAN is higher than in the rest of the world
 - Women are well represented in the trial with a participation rate of >40%
- Baseline characteristics in the exploratory SGLT2i stratum are broadly similar to the main stratum
 - Importantly, the median UPCR is the same as the main stratum
- ALIGN will explore the potential benefits and risks of adding the endothelin A receptor antagonist, atrasentan, to evidence-based therapy including RAS inhibition, in patients with IgAN and severe proteinuria who are at high risk of kidney failure

Acknowledgements

The authors thank all patients and investigators for their participation in the ALIGN trial and Cathy McDonnell and Venkata Ch for their editorial and design support.

Disclosures

HJLH: consulting fees from AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, CSL Behring, Dimerix, Eli Lilly, Gilead, Janssen, Merck, Novartis, Novo Nordisk, and Traveer Therapeutics; research support: AstraZeneca, Boehringer Ingelheim, Janssen, and Novo Nordisk; honoraria from AstraZeneca and Novo Nordisk; travel expenses from Eli Lilly; and The George Institute for Global Health and George Clinical hold kidney disease research trial contracts. DEK: consulting fees from AstraZeneca, Chinook Therapeutics, and Traveer Therapeutics. RAL: fees from Alexion, Aurinia, Beigene, ChemoCentryx, Calliditas, GlaxoSmithKline, HIBio, Novartis, Omeros, Otsuka, Roche, Traveer and Vera Therapeutics; research funding from Apellis, Calliditas, Chinook, Genentech, NIH, Omeros, Otsuka, Roche, Traveer and Vera Therapeutics. A. Levin reports being a member of a steering committee for Chinook/Novartis. A. Liew reports employment with The Kidney & Transplant Practice Pte Ltd; consultancy for Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, AstraZeneca, Baxter Healthcare, Bayer AG, BioCryst Pharmaceuticals, Boehringer-Ingelheim, Chinook Therapeutics, Dimerix Limited, Eledon Pharmaceuticals, Fresenius Medical Care, George Clinical, GlaxoSmithKline, Kira Pharmaceuticals, Prokidea, Otsuka Pharmaceuticals, Vera Therapeutics, Visterra Inc, Zai Lab Co. Ltd; has received speaker's honorarium from AstraZeneca, Baxter Healthcare, Boehringer-Ingelheim, Chinook Therapeutics, Fresenius Medical Care, Otsuka Pharmaceuticals, Vera Therapeutics; and has served as a member of Data Safety and Monitoring Committee for Dimerix Limited and Zai Lab Co. Ltd. HZ: employee of Peking University First Hospital; consultancy fees for being a Steering Committee member from Calliditas, Chinook, Novartis, Omeros, and Otsuka; participated in symposia or panel discussions and received honoraria for scientific presentations from Novartis and Omeros. TG, KS, MC and AK are employees/ex employees of Chinook, a Novartis company. RR is an employee of Novartis. JB reports: consulting and speaker fees from Alnylam, Argenx, Astellas, BioCryst, Calliditas, Chinook, Dimerix, Galapagos, Novartis, Omeros, Traveer Therapeutics, Vera Therapeutics, Visterra; grant support from Argenx, Calliditas, Chinook, Galapagos, GlaxoSmithKline, Novartis, Omeros, Traveer Therapeutics, Visterra; research projects: Argenx, Calliditas, Chinook, Galapagos, GlaxoSmithKline, Novartis, Omeros, Traveer Therapeutics, Visterra; and clinical trials: ADU-CL-19 & ALIGN (Chinook), APPLAUSE (Novartis), ARTEMIS-IGAN (Omeros), ENVISION (Visterra), NeflgARD (Calliditas), ORIGIN (Vera Therapeutics).

References

1. Rovin BH et al. *Kidney Int* 2021; 100: S1–S276.
2. Rauen T et al. *N Engl J Med* 2015; 373: 2225–2236.
3. Kohan DE et al. *Kidney Int Rep* 2023 8:2198–2210.
4. Kim S-G et al. *Nephrol Dial Transplant* 2022; 37: Suppl_3, FC052
5. Wheeler DC et al. *Kidney Int.* 2021;100:215–224